An open question is whether intensive therapy with newer substances, such as SGLT2 inhibitors and angiotensin receptor/neprilysin inhibitors (ARNI), lead to a further reduction in HF outcomes or whether the beneficial effects have maximally reached and thus no further effect can be achieved by polypharmacotherapy. This evidence concerns the gene SLC5A2 and hydrops fetalis.